AIM ImmunoTech (AIM) announced its initiation of a plan to advance Ampligen as a vaccine adjuvant for avian influenza as part of the Company’s ...

Investing.com -- AIM ImmunoTech (NYSE: AIM) Inc. (NYSE American: AIM) has announced its intention to develop Ampligen as a vaccine adjuvant for avian influenza. This move is part of AIM's antiviral ...

NanoViricides, Inc. (NYSE American:NNVC) (the "Company") today announced that it has engaged a Clinical Research Organization (CRO) to conduct a Phase II clinical trial advancing its broad-spectrum ...

GSK is prioritizing development of its hepatitis B treatment bepirovirsen as the pharma ends work on another potential ...

Therefore development of NV-387, a broad-spectrum host-mimetic, direct-acting antiviral drug that the viruses cannot escape even as they change constantly, will be revolutionary once the drug ...

The Vyndaqel family of drugs recorded a remarkable ... reinforcing its pipeline's strength. These investments were essential for continued product development and sustained leadership in the ...

Island Pharmaceuticals Ltd ( ($AU:ILA) ) has issued an announcement. Island Pharmaceuticals Ltd has progressed significantly in its ISLA-101 Phase ...

LAS VEGAS, NV, UNITED STATES, January 20, 2025 /EINPresswire / -- DelveInsight's,“Influenza Pipeline ... broad-spectrum antiviral immunomodulatory nasal spray under clinical development for ...